Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation

[1] Elhai M(2012)Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies Rheumatology (Oxford) 51 1017-1026

[2] Meune C(2017)Systemic sclerosis Lancet 390 1685-1699

[3] Avouac J(2001)A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 44 1351-1358

[4] Kahan A(2017)Update of EULAR recommendations for the treatment of systemic sclerosis Ann Rheum Dis 76 1327-1339

[5] Allanore Y(2018)Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial Rheumatology (Oxford) 57 2106-2113

[6] Denton CP(2017)A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease Arthritis Rheum 46 625-631

[7] Khanna D(2011)Autologous non-myeloablativehaemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet 378 498-506

[8] Pope JE(2019)CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan Arthritis Res Ther. 21 30-2747

[9] Bellamy N(2013)2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative Arthritis Rheum 65 2737-323

[10] Seibold JR(2009)Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases Transpl Infect Dis 11 318-108

[1] Elhai M(2012)Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies Rheumatology (Oxford) 51 1017-1026

[2] Meune C(2017)Systemic sclerosis Lancet 390 1685-1699

[3] Avouac J(2001)A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 44 1351-1358

[4] Kahan A(2017)Update of EULAR recommendations for the treatment of systemic sclerosis Ann Rheum Dis 76 1327-1339

[5] Allanore Y(2018)Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial Rheumatology (Oxford) 57 2106-2113

[6] Denton CP(2017)A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease Arthritis Rheum 46 625-631

[7] Khanna D(2011)Autologous non-myeloablativehaemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet 378 498-506

[8] Pope JE(2019)CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan Arthritis Res Ther. 21 30-2747

[9] Bellamy N(2013)2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative Arthritis Rheum 65 2737-323

[10] Seibold JR(2009)Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases Transpl Infect Dis 11 318-108